No Detail Found!

Elevated Serum Levels of SARS-CoV-2 Anti-Spike S1 RBD IgM, IgG, and IgA in Pfizer-BioNTech Vaccinated, COVID-19 Infected, and COVID-19 Infected after Pfizer-BioNTech Vaccinated Individuals after One Month

Author(s)
Khalid Khalaf Abdullah Collage of medicine, Iraqi University,,Iraq
Ahmed Rushdi Abdullah Collage of medicine, Iraqi University,,Iraq
Abstract
Background: While protective immunity against some viruses, such as coronaviruses, is relatively short-lived, healing from acute infections of many different viruses, such as those caused by yellow fever, polio, measles, and smallpox, can give cell-mediated and humoral immunity for a lifetime. The main element in the long-term prevention of reinfection by most viruses might be due to the specific antibodies generated by plasma cells. Aim: This study aims to estimate the levels of SARS-CoV-2 Anti-Spike S1 RBD IgM, IgA, and IgG in serum among people in Baghdad after one month of receiving the Pfizer-BioNTech vaccine, infected with the SARS-CoV-2 virus after vaccination and COVID-19 infected patients respectively. Methods: A total of 120 volunteers were enrolled in this study, which was conducted between the 1st of November 2022 and the 13th of January 2023, and they were divided into four groups, each group containing 30 individuals. The study groups were categorized after one month into vaccinated with the Pfizer-BioNTech vaccine (BNT162b2), infected with SARS-CoV-2 after Pfizer vaccination, COVID-19 patients, and control. Results: The study presented a significant difference where (P value 0.05) compared to each other. For Anti-Spike S1 RBD IgA and IgG, there was no significant difference (P value >0.05) between the COVID-19-infected patients group and those infected by SARS-CoV-2 after the Pfizer vaccination group. Positive correlations were found among Anti-Spike S1 RBD IgM, IgA, and IgG levels in the serum. Conclusions: Natural infection by SARS-CoV-2 or vaccination with Pfizer-BioNTech (BNT162b2) provides significant humoral Immunological protection.
Publication Details
Page(s) 106-110
Published Journal: Journal of Pioneering Medical Sciences, Volume: 13, Issue: 1, Year: 2024

Request the full text from PASTIC

Keywords
COVID-19, SARS-CoV-2, Covid-19, Pfizer-BioNTech vaccine, Anti-Spike IgG, Anti-Spike IgM, Anti-Spike IgA
References
Lotfi R.,Kalmarzi R. N.,Roghani S. A. .2021 .A review on the immune responses against novel emerging coronavirus (SARS-CoV-2. Immunologic Research, 69(3) : 213-224.
Romano M.,Ruggiero A.,Squeglia F.,Maga G.,Berisio R. .2020 .A structural view of SARS-CoV-2 RNA replication machinery: RNA synthesis, proofreading and final capping. Cells, 9(5) : 1267.
Albasry Z.,Al-Taie A. .2023 .Assessment of acceptance, concerns and side effects towards COVID-19 vaccination among the community: A cross-sectional study from Baghdad, Iraq. Clinical Epidemiology and Global Health, 20 : 101217.
Abdulla Z. A.,Al-Bashir S. M.,Al-Salih N. S.,Aldamen A. A.,Abdulazeez M. Z. .2021 .A summary of the SARS-CoV-2 vaccines and technologies available or under development. Pathogens, 10(7) : 788.
Fraussen J. .2022 .IgM responses following SARS-CoV-2 vaccination: insights into protective and pre-existing immunity. E Bio Medicine, 77 : 103922.
Harrington W. E.,Trakhimets O.,Andrade D. V.,Dambrauskas N.,Raappana A.,Jiang Y.,Sather D. N.,Reports Cell .2021 .Rapid decline of neutralizing antibodies is associated with decay of IgM in adults recovered from mild COVID-19. , 2(4) : 100253.
Khoury D. S.,Cromer D.,Reynaldi A.,Schlub T. E.,Wheatley A. K.,Juno J. A.,Davenport M. P. .2021 .Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature Medicine, 27(7) : 1205-1211.
Yaugel-Novoa M.,Bourlet T.,Paul S. .2022 .Role of the humoral immune response during COVID-19: guilty or not guilty?. Mucosal Immunology, 15(6) : 1170-1180.
Mcgonagle D. .2020 .Since January 2020 Elsevier has created a COVID19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information. , : .
Ruggiero A.,Piubelli C.,Calciano L.,Accordini S.,Valenti M. T.,Dalle Carbonare,Zipeto L.,D. L. .2022 .SARS-CoV-2 vaccination elicits unconventional IgM specific responses in naïve and previously COVID19-infected individuals. EBioMedicine, 77 : 103888.
Röltgen K.,Boyd S. D. .2021 .Antibody and B cell responses to SARS-CoV-2 infection and vaccination. Cell Host & Microbe, 29(7) : 1063-1075.
Hickey T. E.,Kemp T. J.,Bullock J.,Bouk A.,Metz J.,Neish A.,Pinto L. A. .2023 .SARS-CoV-2 IgG Spike antibody levels and avidity in natural infection or following vaccination with mRNA-1273 or BNT162b2 vaccines. Human Vaccines & Immunotherapeutics, 19:2, : 2215677.
Chen X.,Hong J.,Deng L.,Weng H.,Huang T.,Wang L.,Yang J. .2023 .Association between levels of IgG antibodies from vaccines and Omicron symptomatic infection among children and adolescents in China. , 10 : 1240340.
Huang A. T.,Garcia-Carreras B.,Hitchings M. D.,Yang B.,Katzelnick L. C.,Rattigan S. M.,Cummings D. A. .2020 .A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. Nature communications, 11(1) : 4704.
Chan R. W. Y.,Liu S.,Cheung J. Y.,Tsun J. G. S.,Chan K. C.,Chan K. Y. Y.,Lam H. S. .2021 .The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines. , 12 : 744887-744887.
Selma-Royo M.,Bäuerl C.,Mena-Tudela D.,Aguilar-Camprubí L.,Pérez-Cano F. J.,Parra-Llorca A.,Collado M. C. .2022 .AntiSARS-CoV-2 IgA and IgG in human milk after vaccination is dependent on vaccine type and previous SARS-CoV-2 exposure: A longitudinal study. Genome Medicine, 14(1) : 1-11.
Bahl K.,Senn J. J.,Yuzhakov O.,Bulychev A.,Brito L. A.,Hassett K. J.,Ciaramella G. .2017 .Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Molecular Therapy, 25(6) : 1316-1327.
Zheng B.,Peng W.,Guo M.,Huang M.,Gu Y.,Wang T.,Ming D. .1996 .Inhalable nanovaccine with biomimetic coronavirus structure to trigger mucosal immunity of respiratory tract against COVID19. Chemical Engineering Journal (Lausanne, 418 : 129392-129392.
Bates T. A.,McBride S. K.,Leier H. C.,Guzman G.,Lyski Z. L.,Schoen D.,Tafesse F. G. .2022 .Vaccination before or after SARSCoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants. Sci Immunol, : eabn8014-eabn8014.
0

Citations

0

Downloads

39

Views